A
Alexion Pharmaceuticals
World Leader in Treatments for Patients with Devastating and Rare Diseases
At a glance
- Status
- Listed
- Listing
- IPO 1996
Open roles
Alexion Pharmaceuticals in the Boston ecosystem
The Alexion Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- CPCHL Medical Partners
- INInvesco
- OPOak Investment Partners
Series B and later1 investor entered at this stage
- YUYale University
Source: Dealroom Talent Intelligence.
Alumni founders
Former Alexion Pharmaceuticals employees who went on to found companies, sorted by Dealroom signal score.
DTDyne TherapeuticsEst. 2017
Romesh SubramanianUnited States
POPoxelEst. 2009
Pascale FouquerayFrance
ELElevateBioEst. 2018
David HallalUnited States
RARallybioEst. 2018
Jeffrey FryerUnited States
BMBeeline MedicinesEst. 2025
Saqib IslamUnited StatesPatents
254 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Alexion Pharmaceuticals was the backer or acquirer, 2011–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
8 deals across Alexion Pharmaceuticals's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Alexion Pharmaceuticals deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Alexion Pharmaceuticals's portfolio, mapped.
See Alexion Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
TileDB rebrands as Tile.ai, taps ex-Merck CIO as chief executive

